Download PDFPDF

Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Re: clinical endpoints in RA RCTs
    • Johannes W Jacobs, Rheumatologist
    • Other Contributors:
      • Suzan MM Verstappen, Johannes JW Bijlsma

    Dear Editor,

    We do thank Maarten Boers for his complement. We did not employ the composite indices DAS or DAS28 to report clinical efficacy of the two strategy groups in our study, because we had used joint counts not including shoulder joints, which precludes calculating these indices. In our view, shoulder joints are seldom involved in early rheumatoid arthritis and are in addition difficult to score for swelling....

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    clinical endpoints in RA RCTs

    Dear Editor, Verstappen et al are to be congratulated on their 'CAMERA' strategy trial. However, they have chosen not to report the results expressed in the Disease Activity Score (DAS or DAS28). In addition, the international RA core set agreed to in 1992 was not fully applied because physician global assessment was not measured. This is a pity because it precludes calculation of ACR reponse. The lack of both DAS and ACR re...

    Show More
    Conflict of Interest:
    None declared.